Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (211-220 of 471) with videos related to

Pageof 48
Sort By:
Journal of Medical Imaging and Radiation Oncology|June 1, 2013
Treatment response in the neck: p16+ versus p16- oropharyngeal cancerDaisy Mak, Rodney J Hicks, Danny Rischin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2015
15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell CarcinomaKeelan Byrne, Shankar Siva, Lori Chait, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2006
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancerCuong P Duong, Rodney J Hicks, Leann Weih, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
Evaluating the Utility of <sup>18</sup>F-FDG PET/CT in Cancer of Unknown PrimaryTharani Sivakumaran, Anthony Cardin, Jason Callahan, et al.
EJNMMI Radiopharmacy and Chemistry|October 30, 2019
Automated preparation of clinical grade [<sup>68</sup>Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platformMohammad B Haskali, Peter D Roselt, David Binns, et al.
Radiation Oncology (London, England)|December 17, 2014
Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumesJason Callahan, Tomas Kron, Shankar Siva, et al.
Clinical Case Reports|April 12, 2018
Diagnostic challenges in a patient with an occult insulinoma:<sup>68 </sup>Ga-DOTA-exendin-4 PET/CT and <sup>68</sup>Ga-DOTATATE PET/CTElisa Bongetti, Melissa H Lee, David A Pattison, et al.
Internal Medicine Journal|September 20, 2018
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologistsAbby P Douglas, Karin A Thursky, Leon J Worth, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2017
Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysisSue Ping Thang, Mei Sim Lung, Grace Kong, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2014
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursRaghava Kashyap, Michael S Hofman, Michael Michael, et al.
Pageof 48

Showing results (211-220 of 471) with videos related to

Sort By:
Pageof 48
Journal of Medical Imaging and Radiation Oncology|June 1, 2013
Treatment response in the neck: p16+ versus p16- oropharyngeal cancerDaisy Mak, Rodney J Hicks, Danny Rischin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2015
15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell CarcinomaKeelan Byrne, Shankar Siva, Lori Chait, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2006
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancerCuong P Duong, Rodney J Hicks, Leann Weih, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
Evaluating the Utility of <sup>18</sup>F-FDG PET/CT in Cancer of Unknown PrimaryTharani Sivakumaran, Anthony Cardin, Jason Callahan, et al.
EJNMMI Radiopharmacy and Chemistry|October 30, 2019
Automated preparation of clinical grade [<sup>68</sup>Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platformMohammad B Haskali, Peter D Roselt, David Binns, et al.
Radiation Oncology (London, England)|December 17, 2014
Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumesJason Callahan, Tomas Kron, Shankar Siva, et al.
Clinical Case Reports|April 12, 2018
Diagnostic challenges in a patient with an occult insulinoma:<sup>68 </sup>Ga-DOTA-exendin-4 PET/CT and <sup>68</sup>Ga-DOTATATE PET/CTElisa Bongetti, Melissa H Lee, David A Pattison, et al.
Internal Medicine Journal|September 20, 2018
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologistsAbby P Douglas, Karin A Thursky, Leon J Worth, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2017
Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysisSue Ping Thang, Mei Sim Lung, Grace Kong, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2014
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursRaghava Kashyap, Michael S Hofman, Michael Michael, et al.
Pageof 48